Table 1. Adverse events occurring in dogs in the phase I escalation study of EC0531.

Dose of EC0531	Number of dogs receiving that dose	Number of doses given	Adverse events defined by VCOG-CTCAE (G–Grade; DLT–Dose limiting toxicity)
0.18	1	6	1 dog with G1 anorexia
0.20	4	14	1 dog with G2 anorexia
0.22	4	10	1 dog with G1 lethargy
0.24	4	16	1 dog with G2 neutropenia
0.26	6	33	1 dog with G1 lethargy 1 dog with G1 vomiting and G1 neutropenia 1 dog with G2 neutropenia 1 dog with G3 neutropenia (DLT) and G2 diarrhea
0.28	10a,b	63	1 dog with G1 vomitinga 1 dog with G1lethargy and G3 weight loss (DLT)a 1 dog with G4 neutropenia (DLT)b 1 dog with G4 infusion reaction (DLT)b
0.30	2	15	1 dog with G3 neutropenia (DLT)
0.32	1	2	No adverse events observed
0.34	1	5	1 dog with G3 anorexia (DLT)

^aFour dogs initially received a lower dose of EC0531, and then underwent intra-patient dose escalation to receive 0.28 mg/kg EC0531.

^bSix new dogs were enrolled for which their initial dose of EC0531 was 0.28 mg/kg.